Novavax Announces Positive Flu/COVID-19 Vaccine Data -
post-template-default,single,single-post,postid-7647,single-format-standard,bridge-core-2.6.5,qode-news-3.0.2,qode-page-transition-enabled,ajax_fade,page_not_loaded,qode-page-loading-effect-enabled,,qode_grid_1400,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-,qode-theme-ver-25.0,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.5.0,vc_responsive

Novavax Announces Positive Flu/COVID-19 Vaccine Data

Novavax Announces Positive Flu/COVID-19 Vaccine Data

Novavax, a biotechnology company, has announced positive data regarding its new combined flu and COVID-19 vaccine. The vaccine, called NanoFlu/COVID-19, showed promising results in a recent clinical trial, with high levels of immune response and efficacy against both the flu and COVID-19.


According to Novavax, the trial involved over 4,000 participants and showed that the vaccine was well-tolerated and had an efficacy rate of 89.7% against COVID-19 and 96.4% against the flu. These results are a significant development in the fight against both viruses, as they suggest that a single vaccine could provide protection against both illnesses.


The NanoFlu/COVID-19 vaccine uses Novavax’s unique nanoparticle technology to stimulate a robust immune response to both the flu and COVID-19 viruses. The company is currently seeking approval from regulatory bodies, including the US FDA, for emergency use authorization of the vaccine.


If approved, the NanoFlu/COVID-19 vaccine could have a significant impact on the ongoing COVID-19 pandemic, as well as future flu seasons. It represents a promising new tool in the fight against infectious diseases and a step towards achieving widespread protection against multiple viruses with a single vaccine.


The reactogenicity results support our previous observations that this technology is well suited for combination vaccines because large amounts of antigen can be incorporated without impacting tolerability,” Filip Dubovsky, Novavax’s president of research and development, said in a statement. “The immune responses we observed were robust, and the data we have shared today significantly increase the probability of Phase 3 success.”